Cargando…
AKR1C1 promotes non-small cell lung cancer proliferation via crosstalk between HIF-1α and metabolic reprogramming
Non-small cell lung cancer (NSCLC) ranks first among cancer death worldwide. Despite efficacy and safety priority, targeted therapy only benefits ∼30% patients, leading to the unchanged survival rates for whole NSCLC patients. Metabolic reprogramming occurs to offer energy and intermediates for fuel...
Autores principales: | Chang, Lin-Lin, Lu, Pei-Hua, Yang, Wei, Hu, Yan, Zheng, Lin, Zhao, Qiong, Lin, Neng-Ming, Zhang, Wen-Zhou |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034391/ https://www.ncbi.nlm.nih.gov/pubmed/35429904 http://dx.doi.org/10.1016/j.tranon.2022.101421 |
Ejemplares similares
-
AKR1C1 Activates STAT3 to Promote the Metastasis of Non-Small Cell Lung Cancer
por: ZHU, Hong, et al.
Publicado: (2018) -
IDH2 stabilizes HIF‐1α‐induced metabolic reprogramming and promotes chemoresistance in urothelial cancer
por: Shigeta, Keisuke, et al.
Publicado: (2023) -
Aldo–Keto Reductase AKR1C1–AKR1C4: Functions, Regulation, and Intervention for Anti-cancer Therapy
por: Zeng, Chen-Ming, et al.
Publicado: (2017) -
Roles of AKR1C3 in malignancy
por: Xiao, Xin-Zhu, et al.
Publicado: (2021) -
Loss of AKR1B10 promotes colorectal cancer cells proliferation and migration via regulating FGF1-dependent pathway
por: Yao, Yizhou, et al.
Publicado: (2020)